ライフサイエンスコーパス: filgrastim

1 ranulocyte colony-stimulating factor (G-CSF; filgrastim).

2 with granulocyte-colony-stimulating factor (Filgrastim).

3 tively (22% for paclitaxel 175 mg/m2 without filgrastim).

4 after mobilisation with cyclophosphamide and filgrastim.

5 le or greater than those achieved with daily filgrastim.

6 rvested with cyclophosphamide (2 g/m(2)) and filgrastim.

7 yclophosphamide and 10 microg per kg per day filgrastim.

8 57 (40%) erythropoietin, and 17 of 57 (30%) filgrastim.

9 relative to daily subcutaneous injections of filgrastim.

10 benefit to justify paclitaxel 250 mg/m2 plus filgrastim.

11 ilar to that provided by daily injections of filgrastim.

12 ncurrent AC x 4 --> T x 4 every 2 weeks with filgrastim.

13 utropenia and from 36 patients not receiving filgrastim.

14 4-hour infusions and supported with PBSC and filgrastim.

15 Mobilization with filgrastim 10 microg/kg subcutaneous daily for 5 days wa

16 og/kg/d) plus Filgrastim (10 microg/kg/d) or Filgrastim (10 microg/kg/d) alone to mobilize peripheral

17 metHuSCF (5, 10, 15, or 20 microg/kg/d) plus Filgrastim (10 microg/kg/d) or Filgrastim (10 microg/kg/

18 ranulocyte colony-stimulating factor (G-CSF; Filgrastim) 10 microg/kg per day, for 7 days.

19 e colony-stimulating factor (r-met Hu G-CSF; filgrastim; 10 microgram/kg/day for 7 days) was used to

20 jection of pegfilgrastim (sustained-duration filgrastim) 100 micro g/kg per chemotherapy cycle (n = 3

21 in the patients who received r-metHuSCF and Filgrastim (12.5 v 23 days).

22 ere randomized to receive placebo (n=243) or filgrastim 300 microg/day (n=237), in addition to standa

23 Standard antibiotic therapy with or without filgrastim (300 microg/day) or placebo administered as a

24 = 33) with daily subcutaneous injections of filgrastim 5 micro g/kg (n = 33) in patients receiving s

25 e 20 mg/m(2) iv days1 through 5, followed by filgrastim 5 microg/kg subcutaneous starting approximate

26 5 mg/m2 and cyclophosphamide 750 mg/m2, with filgrastim 5 microG/kg/d subcutaneously beginning 24 hou

27 All patients also received filgrastim 5 micrograms/kg administered subcutaneously b

28 All patients received filgrastim (5 mcg/kg) daily until the absolute neutrophi

29 nd etoposide (500 mg/m2) for 14 cycles, with filgrastim (5 mg/kg per day; maximum, 300 mg) between cy

30 lung cancer were randomized to receive daily filgrastim (5 microg/kg/d) or a single injection of SD/0

31 Filgrastim (5 micrograms/kg/d) was administered subcutan

32 The duration of administration of SCF and filgrastim (7, 10, or 13 days) did not significantly aff

33 s of placebo (n = 21) or one of two doses of filgrastim (75 microg [n = 20] or 300 microg [n = 20]) f

34 ranulocyte colony-stimulating factor (G-CSF, filgrastim), a cytokine that initiates proliferation and

35 ient hospital department vs office practice, filgrastim: adjusted difference, -16.1 [95% CI, -18.1 to

36 ership status (for-profit vs not-for-profit, filgrastim: adjusted difference, -17.4 [95% CI, -21.6 to

37 g, hematologist-oncologists vs primary care, filgrastim: adjusted difference, -3.0 [95% CI, -5.4 to -

38 imab prescribing volume (high vs low volume, filgrastim: adjusted difference, 3.6 [95% CI, 1.5 to 5.8

39 mg/m2 and cyclophosphamide 1,250 mg/m2 with filgrastim administered every 21 days are the doses reco

40 itive stem cells to injured myocardium after filgrastim administration (control vs SDF-1-expressing c

41 Contemporaneous with filgrastim administration for stem cell mobilization, th

42 filgrastim injection with daily subcutaneous filgrastim administration in pediatric patients receivin

43 Filgrastim administration was accompanied by similar sym

44 can be concluded that the administration of filgrastim after allogeneic blood stem cell transplantat

45 o receive one dose of pegfilgrastim or daily filgrastim after chemotherapy.

46 o determine whether further stimulation with filgrastim after transplantation would affect hematopoie

47 g filgrastim followed by cladribine and then filgrastim again to determine if filgrastim would lead t

48 The addition of filgrastim allowed escalation of the topotecan dose to t

49 Patients received either filgrastim alone (10 microg/kg/d for 7 days) or the comb

50 han 10 microg/kg/d, than for those receiving filgrastim alone (7.7 v 3.2 x 10(6)/kg, P < .05).

51 kaphereses) compared with patients receiving Filgrastim alone (median, 6 or more leukapherses; ie, <5

52 = 100) compared with 47% of those receiving Filgrastim alone (n = 103) reached the CD34(+) cell targ

53 tHuSCF and Filgrastim (N = 18) compared with Filgrastim alone (N = 5).

54 no major differences in outcomes between the filgrastim alone and the sequential regimens.

55 ion with Filgrastim at 10 micrograms/kg/d or Filgrastim alone at 10 micrograms/kg/d, from 203 patient

56 Stem-cell mobilisation with filgrastim alone did not lead to engraftment of bone-mar

57 obilization of PBSC was achieved with either filgrastim alone or in combination with cyclophosphamide

58 It was concluded that filgrastim alone or sequential sargramostim and filgrast

59 Treatment groups mobilized with filgrastim alone or with the cytokine combination had si

60 6)/kg) 7-day combination groups than for the filgrastim alone patients (median, 3.2 x 10(6)/kg).

61 enitor cell (PBPC)-mobilization regimen than Filgrastim alone.

62 Filgrastim, an analog for granulocyte colony-stimulating

63 7 days) or the combination of 10 microg/kg/d filgrastim and 5 to 30 microg/kg/d SCF for either 7, 10,

64 men with breast cancer chemotherapy received filgrastim and 6.8% received epoetin.

65 d as a 1-hour infusion at 60 mg/m(2) without filgrastim and at 60, 70, and 80 mg/m(2) with filgrastim

66 Thirty-five patients received filgrastim and cladribine and were compared with 105 his

67 etect any clinical advantage from the use of filgrastim and cladribine in the treatment of HCL.

68 ve times and 65 times more likely to receive filgrastim and epoetin, respectively, after controlling

69 recommendations include the addition of tbo-filgrastim and filgrastim-sndz, moderation of the recomm

70 tional study examines utilization trends for filgrastim and infliximab products and their biosimilars

71 nd topotecan can be safely administered with filgrastim and PBSC support.

72 er for patients receiving the combination of filgrastim and SCF, at doses greater than 10 microg/kg/d

73 ease in absolute neutrophil count, safety of filgrastim, and frequency of nosocomial infections (pneu

74 travenous infusion (CIVI) for 4 days without filgrastim, and paclitaxel 17.5 mg/m(2)/d CIVI for 4 day

75 e model protein lysozyme, the biotherapeutic filgrastim, and the Fc part of immunoglobulin G1.

76 The administration of filgrastim appears to be a safe and effective supportive

77 Hematopoietic cytokines such as filgrastim are used extensively to stimulate granulocyte

78 BSCT were randomly assigned to receive daily filgrastim at 10 microg/kg or placebo starting on the da

79 F) at 20 micrograms/kg/d in combination with Filgrastim at 10 micrograms/kg/d or Filgrastim alone at

80 y cycle is comparable to daily injections of filgrastim at 5 microg/kg for pediatric sarcoma patients

81 PBSC donors were treated with 5 to 7 days of filgrastim at a dose of 16 microg/kg/d and underwent 1 t

82 esna was administered similarly (both arms); filgrastim began on day 4 (arm 2).

83 Filgrastim caused a dose-dependent increase in absolute

84 erapy, median ANC nadirs were similar in the filgrastim cohort and the cohort receiving SD/01 30 micr

85 both groups, CD34(+) cells were mobilized by filgrastim, collected via apheresis, and labeled with te

86 (range, 9-20 days) for patients who received filgrastim compared with 15 days (range, 10-22 days) for

87 (range, 8-35 days) for patients who received filgrastim compared with 15.5 days (range, 8-42 days) fo

88 stim closely match the stability patterns of filgrastim, consistent with a key role for pegfilgrastim

89 Doubling the filgrastim dose from 5 to 10 microg/kg did not reduce th

90 and 18% on the 5-microg/kg and 10-microg/kg filgrastim dose, respectively (22% for paclitaxel 175 mg

91 stim dose of 100 microg/kg (n = 38) or daily filgrastim doses of 5 microg/kg (n = 6) after chemothera

92 Omission of routine peg-filgrastim during dose-dense paclitaxel according to a p

93 Eight patients (6.4%) received peg-filgrastim during the trial.

94 nia (SCN), known under the generic drug name filgrastim, exemplifies this challenge.

95 tients received fludarabine, cytarabine, and filgrastim followed 2 weeks later by infusion of donor l

96 We performed a study of priming filgrastim followed by cladribine and then filgrastim ag

97 y topotecan 0.75 mg/m2 daily for 5 days with filgrastim for amelioration of neutropenia.

98 geable levels of toxicity when combined with filgrastim for PBPC mobilization.

99 actor (SCF) administered in combination with filgrastim for the mobilization of peripheral blood prog

100 Food and Drug Administration approved G-CSF (filgrastim) for the treatment of congenital and acquired

101 ients were also randomly assigned to receive filgrastim (G-CSF) from day 0 until neutrophil count was

102 cyclophosphamide (CPA)/paclitaxel (Txl) and filgrastim (granulocyte colony-stimulating factor [G-CSF

103 peripheral-blood progenitor-cell (PBPC) and filgrastim (granulocyte colony-stimulating factor [G-CSF

104 This study evaluated the effect of filgrastim (granulocyte colony-stimulating factor [G-CSF

105 dy was performed to determine the effects of filgrastim (granulocyte colony-stimulating factor; G-CSF

106 re randomized to have HPC mobilization using filgrastim [granulocyte-colony-stimulating factor (G-CSF

107 The filgrastim group also had a trend for earlier discharge

108 grade 4 neutropenia in the pegfilgrastim and filgrastim groups was 69% and 68%, respectively.

109 The group receiving filgrastim had a shorter time to neutrophil levels great

110 received sargramostim, patients who received filgrastim had faster recovery of an absolute neutrophil

111 Filgrastim or r-metHuSCF in combination with Filgrastim); however, when prior chemotherapy was taken

112 A x 4 --> T x 4 --> C x 4 every 2 weeks with filgrastim, (III) concurrent AC x 4 --> T x 4 every 3 we

113 , prednisone, and rituximab (DA-EPOCH-R) and filgrastim in untreated MGZL.

114 ranulocyte colony-stimulating factor (G-CSF; filgrastim) in an attempt to maximize delivered dose-int

115 Filgrastim increased the white blood cell count to a med

116 Filgrastim increased WBC counts (baseline median, 13.3x1

117 for at least 3 years (bevacizumab, epoetin, filgrastim, infliximab, pegfilgrastim, rituximab, and tr

118 reatment was supported by daily subcutaneous filgrastim injections and reinfusion of 750 mL of autolo

119 In conclusion, SCF plus Filgrastim is a more effective peripheral blood progenit

120 Once a patient received peg-filgrastim, it was administered in all future cycles.

121 Filgrastim largely obviates neutropenic fever and allows

122 Fludarabine, cyclophosphamide, and filgrastim make up a highly active and well-tolerated re

123 tatistical significance, which suggests that filgrastim may reduce the decline of HIV-1 RNA loads.

124 et yield for the patients receiving SCF plus Filgrastim (median, 4 leukaphereses) compared with patie

125 The study concluded that filgrastim mobilization, large volume apheresis, process

126 g donor adverse events (AEs) associated with filgrastim mobilized peripheral blood stem cell (PBSC) c

127 y), sirolimus, and infusion of unmanipulated filgrastim mobilized peripheral blood stem cells (5.5-31

128 igned to receive either allogeneic marrow or filgrastim-mobilized blood stem cell transplantation.

129 Marrow (BMT) was used for 44 patients and filgrastim-mobilized blood stem cells (SCT) for 41 patie

130 de that the transplantation of unmanipulated filgrastim-mobilized blood stem cells may result in a re

131 In a prospective randomized clinical trial, filgrastim-mobilized PBPCT resulted in faster recovery o

132 om a randomized clinical trial that compared filgrastim-mobilized PBPCT versus ABMT following carmust

133 om a randomized clinical trial that compared filgrastim-mobilized PBPCT versus ABMT.

134 y for 2 days) followed by transplantation of filgrastim-mobilized peripheral blood cells from HLA-ide

135 ly assigned to receive either bone marrow or filgrastim-mobilized peripheral-blood cells from HLA-ide

136 rials have shown that the transplantation of filgrastim-mobilized peripheral-blood stem cells from HL

137 Filgrastim-mobilized stem cells from HLA-identical relat

138 s, 63% of the patients treated with SCF plus Filgrastim (n = 100) compared with 47% of those receivin

139 (4)/kg) in patients receiving r-metHuSCF and Filgrastim (N = 18) compared with Filgrastim alone (N =

140 ifty-six patients were randomized to receive filgrastim (n = 51), sargramostim (n = 52), or sargramos

141 52), or sargramostim for 5 days followed by filgrastim (n = 53) after MC with either cyclophosphamid

142 (22.2%) were associated with biosimilar use (filgrastim, neutropenia: adjusted difference, -2.0 [95%

143 sargramostim, or sequential sargramostim and filgrastim on CD34(+) cell yields and morbidity after my

144 ilgrastim and at 60, 70, and 80 mg/m(2) with filgrastim on day 1, and topotecan was administered at 0

145 g/m2 every 2 weeks x four cycles), requiring filgrastim on days 3 through 10 of each cycle has been s

146 ic characteristics, specialty, and volume of filgrastim or infliximab biologic administration; hospit

147 Administration of a filgrastim or infliximab biosimilar.

148 h biosimilar administrations, including high filgrastim or infliximab prescribing volume (high vs low

149 y treatment cohort and mobilization regimen (Filgrastim or r-metHuSCF in combination with Filgrastim)

150 eral-blood stem cells (PBSCs) mobilized with filgrastim or the sequential regimen received higher num

151 Filgrastim, or granulocyte colony-stimulating factor, re

152 sical status starting with administration of filgrastim (PBSC donors) or after the marrow collection

153 so randomly assigned to 5 or 10 microg/kg of filgrastim per day subcutaneously.

154 limiting adverse effect, and the addition of filgrastim permitted the maintenance of dose-intensity i

155 After filgrastim priming, the median ANC increased from 0.9 x

156 fee-for-service beneficiaries who received a filgrastim product or an infliximab product between the

157 The hypothesis that filgrastim (r-met-huG-CSF) activates replication of mino

158 is study assessed the safety and efficacy of filgrastim (r-metHuG-CSF [recombinant human methionine g

159 pheral-blood cells mobilized with the use of filgrastim (recombinant granulocyte colony-stimulating f

160 Our results suggest that the CDE and filgrastim regimen is tolerable and effective for patien

161 Filgrastim regularly increases the ANC in patients with

162 ted with a 95.7% reduction in the use of peg-filgrastim relative to the current standard of care.

163 cosylated recombinant forms, lenograstim and filgrastim, respectively, are used clinically to manage

164 The final filgrastim sample included 25 870 patients (11 857 [45.8

165 of this study was to compare the effects of filgrastim, sargramostim, or sequential sargramostim and

166 ranulocyte colony-stimulating factor (G-CSF; filgrastim) shortens the time to neutrophil recovery aft

167 s include the addition of tbo-filgrastim and filgrastim-sndz, moderation of the recommendation regard

168 Early studies suggest that filgrastim-stimulated bone marrow may confer some of the

169 ogenitors in the blood stem cell grafts from filgrastim-stimulated donors.

170 e randomized to receive 10 microg/kg per day filgrastim subcutaneously from day 1 through neutrophil

171 Filgrastim, sulfamethoxazole/trimethoprim, and acyclovir

172 ted of fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated

173 to respond or progressed could then receive filgrastim support or paclitaxel administered over 96 ho

174 Induction CIP was well tolerated (with filgrastim support) and active (partial response rate, 4

175 clitaxel 17.5 mg/m(2)/d CIVI for 4 days with filgrastim support.

176 and mitoxantrone/diaziquone with or without filgrastim support.

177 d to achieve an AUC of 7 mg/mL x minute with filgrastim support.

178 table hematopoietic toxicity with the use of filgrastim support.

179 lerated by a large fraction of patients with filgrastim support.

180 nrolled at a starting dose of 8 mg/m2/d with filgrastim support.

181 apy was dose-intensified CHOP (CHOP-DI) with filgrastim support.

182 of 8 mg/m2/d was neutropenia with or without filgrastim support.

183 table hematopoietic toxicity with the use of filgrastim support.

184 o achieve an AUC of 7 mg/mL x minute without filgrastim support; (2) paclitaxel 135 mg/m2 with a carb

185 d to achieve an AUC of 9 mg/mL x minute with filgrastim support; and (3) paclitaxel 225 mg/m2 with a

186 135 mg/m2 over 3 hours every 3 weeks without filgrastim support; the dose was increased as tolerated

187 ation with 600 mg/m2 of cyclophosphamide and filgrastim, the MTD of mitoxantrone is 28 mg/m2, a dose

188 Six patients required filgrastim therapy for neutropenia.

189 sion, patients were randomly assigned G-CSF (filgrastim) therapy (n = 20) or placebo (n = 20) for 7 d

190 He started treatment with filgrastim to facilitate collection of circulating hemat

191 ne and etoposide combined with rituximab and filgrastim to mobilize autologous peripheral-blood stem

192 ed from 36 HIV-1-infected patients receiving filgrastim to prevent neutropenia and from 36 patients n

193 The addition of filgrastim to the antibiotic and supportive care treatme

194 ranulocyte colony-stimulating factor (G-CSF, filgrastim) to determine the effect of drug sequence on

195 greater than 1.0 x 10(9)/L was 9 days in the filgrastim-treated group versus 22 days among historic c

196 fter cladribine, the median nadir ANC in the filgrastim-treated group was 0.53 x 10(9)/L compared wit

197 Filgrastim-treated patients received a median of 11 inje

198 rees of env sequences from 3 subjects during filgrastim treatment contained unique intrasubject subcl

199 plasma quasi species present 5 years before filgrastim treatment than were the majority of the pretr

200 ence that increased HIV-1 replication during filgrastim treatment was associated with activation of H

201 th activation of HIV-1 variants that, before filgrastim treatment, were minor components of the plasm

202 unique subclusters were not detected before filgrastim treatment, yet they composed 40%-70% of the p

203 n whom plasma HIV-1 RNA had increased during filgrastim treatment.

204 n of PBPCs, patients received 10 microg/kg/d filgrastim until absolute neutrophil count recovery.

205 asibility and safety of omitting routine peg-filgrastim use during the paclitaxel portion of the dose

206 0) HIV-1 RNA level for individuals receiving filgrastim versus those not receiving the drug of 5.11 v

207 Peg-filgrastim was administered after paclitaxel only if pat

208 Filgrastim was administered at 5 micrograms/kg/d subcuta

209 Overall, peg-filgrastim was administered in only 4.3% of paclitaxel c

210 Omission of peg-filgrastim was not causally related to noncompletion of

211 In this patient population, use of filgrastim was safe and the agent appeared to reduce the

212 ll be required to validate this observation, filgrastim was safe and well tolerated when administered

213 A dose of 5 microg/kg of G-CSF (Filgrastim) was given subcutaneously each day for 5 days

214 Results Pegfilgrastim and filgrastim were similar for all efficacy and safety end

215 grastim alone or sequential sargramostim and filgrastim were superior to sargramostim alone for the m

216 hylactic corticosteroids, ciprofloxacin, and filgrastim were used.

217 Accordingly, the routine adjunctive use of filgrastim with cladribine in the treatment of HCL canno

218 ion of 20 microg/kg/d SCF and 10 microg/kg/d filgrastim with daily apheresis beginning on day 5 was s

219 se of granulocyte colony-stimulating factor (filgrastim) with or without transplantation of syngeneic

220 when given on an every 2-week schedule with filgrastim, with encouraging antitumor activity observed

221 , prednisone, and rituximab (DA-EPOCH-R) and filgrastim without radiotherapy in 51 patients with untr

222 ne and then filgrastim again to determine if filgrastim would lead to a reduction of neutropenia and

223 Patients who received filgrastim yielded more CD34(+) cells (median, 7.1 v 2.0